Collegium Pharmaceutical, Inc. (COLL) News
Filter COLL News Items
COLL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COLL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest COLL News From Around the Web
Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.
Collegium Pharmaceutical Unveils 2025 Financial ProjectionsThe latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue. The company completed the integration of Ironshore Therapeutics and plans targeted investments in Jornay PM to drive growth, aiming for significant top- and bottom-line growth and long-term shareholder value. More about Collegium |
Collegium Provides 2025 Financial Guidance and Business Update– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. “In 20 |
Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focusCollegium Pharmaceutical, Inc. ( NASDAQ:COLL ) shareholders might be concerned after seeing the share price drop 22% in... |
Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings SuggestCollegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) earnings announcement last week was disappointing for investors... |
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
Collegium to Participate in Upcoming Investor ConferencesSTOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences: Jefferies London Healthcare ConferenceFireside Chat Date and Time: Tuesday, November 19, 2024, at 1:30 p.m. GMT Piper Sandler 36th Annual Healthcare ConferenceFireside Chat D |
Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsCollegium Pharmaceutical ( NASDAQ:COLL ) Third Quarter 2024 Results Key Financial Results Revenue: US$159.3m (up 17... |
Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...Collegium Pharmaceutical Inc (COLL) reports a 17% increase in total net product revenues and outlines strategic plans for growth in the ADHD market. |
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately. |
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 EarningsWhile the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |